DS
PCVX icon

David Shaw’s Vaxcyte PCVX Stock Holding History

David Shaw’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Sell
1,901,872
-963,446
-34% -$52.3M 0.05% 415
2026
Q1 		$167M Sell
2,865,318
-765,735
-21% -$41.6M 0.1% 233
2025
Q4 		$168M Sell
3,631,053
-659,737
-15% -$29.5M 0.09% 241
2025
Q3 		$155M Buy
4,290,790
+1,202,340
+39% +$39.8M 0.09% 261
2025
Q2 		$100M Buy
3,088,450
+2,220,559
+256% +$72.8M 0.07% 330
2025
Q1 		$32.8M Buy
867,891
+92,238
+12% +$7.37M 0.03% 669
2024
Q4 		$63.5M Buy
775,653
+352,155
+83% +$35M 0.05% 470
2024
Q3 		$48.4M Buy
423,498
+193,291
+84% +$17.4M 0.04% 519
2024
Q2 		$17.4M Sell
230,207
-137,042
-37% -$9.33M 0.02% 968
2024
Q1 		$25.1M Sell
367,249
-71,062
-16% -$4.92M 0.02% 804
2023
Q4 		$27.5M Sell
438,311
-100,073
-19% -$5.2M 0.02% 749
2023
Q3 		$27.4M Sell
538,384
-274,528
-34% -$13.5M 0.03% 684
2023
Q2 		$40.6M Buy
812,912
+18,005
+2% +$853K 0.04% 511
2023
Q1 		$29.8M Sell
794,907
-177,414
-18% -$7.53M 0.03% 675
2022
Q4 		$46.6M Buy
+972,321
New +$38.2M 0.05% 458

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

David Shaw's PCVX Position: Q2 2026 in Review

David Shaw reduced its Vaxcyte (PCVX) stake by 34% in Q2 2026, selling an estimated $52.3M and leaving 1,901,872 shares worth $111M. The position accounts for 0.05% of the portfolio, ranked #415.

David Shaw first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $168M in Q4 2025. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • David Shaw held 1,901,872 shares of Vaxcyte worth $111M as of Q2 2026.
  • David Shaw sold 963,446 Vaxcyte shares in Q2 2026, an estimated $52.3M.
  • Vaxcyte made up 0.05% of David Shaw's portfolio in Q2 2026, its #415 holding.
  • David Shaw first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
  • David Shaw's Vaxcyte position peaked at $168M in Q4 2025.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.